Astria Therapeutics, Inc. (NASDAQ:ATXS) Q4 2022 Earnings Call Transcript

Andy Nichols: Yes. So yes, we are fortunate that the injection site reaction data are very reassuring so far. We’ve had a few mild. The most common one is just redness which is fairly common when you inject anything on your skin. So, so far, it is comforting to know that there’s nothing here that makes us concerned about moving forward. The formulation right now is 150 milligrams per ml, which is standard for a subcutaneously administered monoclonal antibody. There may be opportunities to concentrate that a bit more to allow for less volume that could potentially decrease the frequency of injection site reactions. And that’s work that’s ongoing and we will certainly be able to fill you and the community in about that as those efforts continue.

Michael Higgins: I think I’ve one more in here. A question on the IV. If you could review for us your rationale for testing an IV, the 600 milligrams in the Phase 1a again. Thanks.

Andy Nichols: Sure. So there’s two main. One is that 600 milligrams IV will provide a very high concentration. And what we are more concerned about in the Phase 1a data is the effect of the concentration than anything else. And that will allow us to — the ability to get to a high concentration and watch their PK profile, PD profile, ultimately, safety profile over time over the full 8 months of follow-up. The second is that we have some additional questions regarding bioavailability and absorption that — comparing the IV — 600 milligrams IV to the 600 milligram subcutaneous dose would help us answer.

Michael Higgins: Appreciate that. Thanks, guys.

Andy Nichols: Sure.

Operator: Thank you for the questions, Michael. This concludes our question-and-answer session. I will now turn the call back over to Jill.

Jill Milne: Thank you, Clara. Thank you all for joining our call this morning and for your continued support of Astria. We will keep you updated as we execute on our STAR-0215 program, the ALPHA-STAR trial and share other areas of progress in the company. We look forward to speaking with you again. Andrea?

Andrea Matthews: That concludes today’s call. A webcast replay will be available for 90 days via the Investor Relations page on our website at www.astriatx.com. Thank you.